McKesson Corporation vs Snowflake Inc — how do they compare? McKesson Corporation trades at $828.8 (market cap $97.35B), while Snowflake Inc trades at $278.9 (market cap $95.09B). The key difference: McKesson Corporation and Snowflake Inc are close in size by market cap, and McKesson Corporation pays a 0.39% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| MCK | SNOW | |
|---|---|---|
Market Cap | $97.35B | $95.09B |
Sector | Health | Technology |
52-Week High | $995.69 | $280.16 |
52-Week Low | $659.01 | $121.11 |
Enterprise Value | $101.98B | $94.90B |
Dividend Yield | 0.39% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Snowflake (SNOW) trades at $274.09, up 1.93% with bullish technical indicators and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $0.39 exceeding expectations of $0.3193. Revenue growth remains robust at $3.63 billion in 2025, though the company continues to operate at a net loss of -$1.29 billion. Technical analysis indicates bullish momentum with current price near resistance at $274, while institutional sentiment remains positive with 81% buy ratings.
Snowflake presents a growth investment opportunity with accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces significant execution risks from persistent losses and intense cloud competition. The consensus price target of $299.58 suggests 9% upside potential, though profitability challenges and high valuation multiples require careful monitoring of margin improvement trends.
Trailing returns across standard periods
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →